JNJ Stock Up 6.8% after 7-Day Win Streak
Johnson & Johnson (JNJ) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.8% return. The company has gained about $30 Bil in value over the last 7 days, with its current market capitalization at about $448 Bil. The stock remains 31.7% above its value at the end of 2024. This compares with year-to-date returns of 14.1% for the S&P 500.
JNJ provides healthcare products globally, including baby care, pharmaceuticals for inflammatory diseases, and MedTech electrophysiology solutions for cardiovascular treatment. After this rally, is JNJ still a buy – or is it time to lock in gains? Deep dive with Buy or Sell JNJ.
Comparing JNJ Stock Returns With The S&P 500
The following table summarizes the return for JNJ stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | JNJ | S&P 500 |
|---|---|---|
| 1D | 0.3% | 0.3% |
| 7D (Current Streak) | 6.8% | 0.3% |
| 1M (21D) | 4.5% | 4.6% |
| 3M (63D) | 20.5% | 7.8% |
| YTD 2025 | 31.7% | 14.1% |
| 2024 | -4.8% | 23.3% |
| 2023 | -8.6% | 24.2% |
| 2022 | 6.0% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 88 S&P constituents with 3 days or more of consecutive gains and 56 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 17 | 50 |
| 4D | 62 | 2 |
| 5D | 7 | 2 |
| 6D | 0 | 0 |
| 7D or more | 2 | 2 |
| Total >=3 D | 88 | 56 |
Key Financials for Johnson & Johnson (JNJ)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $85.2 Bil | $88.8 Bil |
| Operating Income | $23.4 Bil | $22.1 Bil |
| Net Income | $35.2 Bil | $14.1 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $21.9 Bil | $23.7 Bil |
| Operating Income | $6.3 Bil | $6.8 Bil |
| Net Income | $11.0 Bil | $5.5 Bil |
While JNJ stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.